- BioSapien’s pre-Series A funding has surpassed $8 million, providing substantial capital to accelerate the development of its MediChip™ platform and enhance operational capabilities.
- The round saw participation from prominent investors, including Globivest, the first women-led, gender-lens venture capital fund from the MENA region, alongside leading funds such as Global Ventures, Golden Gate Ventures, and Dara Holdings.
- BioSapien is committed to delivering precise and practical medical solutions through MediChip™, a technology poised to be a scientific breakthrough in localized cancer treatment.
BioSapien, a pioneering UAE-based biotechnology company, has successfully extended its pre-Series A funding round to over $8 million. This significant investment underscores strong investor confidence in the company’s vision to revolutionize localized cancer treatment through its innovative MediChip™ platform.
BioSapien’s extended funding round is a clear indicator of its rapid growth and the growing trust investors place in its cutting-edge technology. The company initially raised $5.5 million in December 2024, led by Global Ventures, and further extended the round to $7 million in January 2025. Now, surpassing $8 million, this trajectory highlights not only the immense commercial potential of MediChip™ but also the profound humanitarian mission driving the company.
Globivest: A Strategic Partner with Impact at its Core
The involvement of Globivest, the MENA region’s first women-led venture capital fund, adds a unique dimension to this funding round. Globivest’s approach extends beyond financial backing, fostering a strategic partnership that aligns financial returns with social and environmental impact, drawing inspiration from the World Health Organization’s “One Health” concept.
Dr. Khatija Ali, CEO of BioSapien, emphasized the importance of this partnership: “Establishing a strong balance sheet and attracting high-quality talent are two of the greatest challenges for young, fast-growing companies. Therefore, I am delighted to announce an extension of BioSapien’s pre-Series A funding round. Globivest is not just an investor; they are a strategic partner who shares our vision… a vision of precision medicine with a global impact, made locally accessible.”
Dr. Laura-Joy Boulos, Partner at Globivest, added, “At Globivest, we back companies that don’t just promise innovation – they deliver transformative, science-backed solutions with the power to shift paradigms. BioSapien’s MediChip™ platform is a breakthrough in localized cancer treatment – scalable, precise, and deeply aligned with our One Health mission.”
MediChip™: A New Horizon in Localized Cancer Treatment
Through its MediChip™ platform, BioSapien is introducing a revolutionary approach to localized cancer treatment, focusing on precision medicine that is both practical and safe. This innovative method is expected to significantly transform conventional treatment modalities, offering patients more effective and secure options. BioSapien’s dedication to providing medical solutions with global impact and local availability positions it at the forefront of companies that successfully blend scientific innovation with social responsibility.
العربية (Arabic) To read the article in Arabic, click here
